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Abstract
Several studies have demonstrated that the passive transfer of protective antigen (PA)-neutralizing antibodies can protect
animals against Bacillus anthracis infection. The standard protocol for the isolation of PA-neutralizing monoclonal antibodies
is based upon a primary selection of the highest PA-binders by ELISA, and usually yields only few candidates antibodies. We
demonstrated that by applying a PA-neutralization functionality-based screen as the primary criterion for positive clones, it
was possible to isolate more than 100 PA-neutralizing antibodies, some of which exhibited no measurable anti-PA titers in
ELISA. Among the large panel of neutralizing antibodies identified, mAb 29 demonstrated the most potent activity, and was
therefore chimerized. The variable region genes of the mAb 29 were fused to human constant region genes, to form the
chimeric 29 antibody (cAb 29). Guinea pigs were fully protected against infection by 40LD50 B. anthracis spores following
two separate administrations with 10 mg/kg of cAb 29: the first administration was given before the challenge, and a
second dose was administered on day 4 following exposure. Moreover, animals that survived the challenge and developed
endogenous PA-neutralizing antibodies with neutralizing titers above 100 were fully protected against repeat challenges
with 40LD50 of B. anthracis spores. The data presented here emphasize the importance of toxin neutralization-based screens
for the efficient isolation of protective antibodies that were probably overlooked in the standard screening protocol. The
protective activity of the chimeric cAb 29 demonstrated in this study suggest that it may serve as an effective
immunotherapeutic agent against anthrax.
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Introduction
The anthrax bio-terror incidents in the USA clearly demonstrated
the threat posed by the intentional release of infectious agents, and
highlighted the need for improved prophylactic approaches against
anthrax [1,2]. In a post-exposure scenario, the efficacy of the current
FDA-approved, protective antigen (PA)-based vaccine (AVA, Bio-
thrax
TM, Bioport Corp., Lansing, MI) is limited, since a multiple-dose
schedule is required for a protective-antibody titer to develop [3,4].
Indeed, when immunization is initiated after the onset of symptoms,
mortality rates due to anthrax are high [5], emphasizing the need for
complimentary therapies for post-exposure events.
Antibiotic therapy is effective for the treatment of anthrax when
administered soon after infection and before the onset of symptoms.
Yet, due to the possible long-term survival of anthrax spores in the
lungs, the updated CDC recommendations following potential
exposure to aerosolized B. anthracis spores include a prolonged
antibiotic treatment period (at least 60 days) combined with active PA-
immunization [6]. However, antibiotic prophylaxis can be problem-
atic in situations where their use is contraindicated, or in cases
involving antibiotic resistant B. anthracis s t r a i n s[ 7 ] .F u r t h e r m o r e ,i n
cases where disease has progressed and a substantial amount of
anthrax toxins have been delivered to the bloodstream, antibiotic
treatment is of less value. In these scenarios, the passive transfer of
neutralizing antibodies directed against either PA or lethal factor (LF)
can provide immediate, specific and low-toxicity protection.
Neutralizing antibody titers are mainly defined by their in vitro
activity,whichisbasedupontheinhibitionofPA-LFtoxincomplex-
mediated cell-death (LeTx assay). It has previously been shown that
the results of the LeTx assay can serve as a surrogate marker to
predict an antibody’s neutralization potential against anthrax
challenges in vivo [8]. The typical method for the elucidation of
PA-neutralizing monoclonal antibodies includes a wide screen and
the selection of antibodies that bind to adsorbed PA (direct ELISA
format), and only then the best binders were screened for their
ability toneutralizePAintheLeTx assay.Although this strategyhas
led to the isolation of protective antibodies, it is not very effective,
with each screen yielding only 3–10 candidate antibodies [9–14].
Here,webased our primaryscreenupontheLeTxassay,inorder
to generate a wide panel of PA-neutralizing monoclonal antibodies.
Moreover, we reasoned that the level of PA-neutralizing antibodies
in mouse sera will influence the screen outcome, and therefore a
specific enrichment of the subset of these antibodies was desired.
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6351The results of this study support the notion that high anti-PA titers
are not always associated with PA-neutralizing antibody titers. By
applying an automated functionally-based screen, 101 hybridoma
cell-linesexhibitingPA-neutralizing activity were isolated. The most
potent antibody (cAb 29) was chimerized and shown to be highly
effective in neutralizing anthrax toxin and in protecting guinea pigs
against lethal doses of anthrax spores.
Materials and Methods
Production and purification of PA and vaccine
formulation
B. anthracis strain V770-NPI-R (ATCC 14185) was anaerobically
grown, as described previously [15]. After 24 hours of growth,
bacteria were removed by microfiltration (0.2 mm), while the PA-
containing supernatant was concentrated by ultrafiltration (30K
M.W. cutoff) and dialyzed against 20 mM phosphate buffer
(pH=8.0). Purification of PA and LF was carried out by Q-
Sepharose chromatography, essentially as described previously [8].
Formulation of PA vaccine in alum was prepared by adsorption of
the purified PA at a final concentration of 50 mg/ml to Alum
hydroxide gel (0.32% w/v), as described previously [8].
PA-specific antibody titer determination using direct and
indirect-ELISA
Direct-ELISA for anti-PA antibody titration was performed in
96-well microtiter plates (Nunc, Roskilde, Denmark) using an
RMP200 (TECAN, Switzerland) robotic system. In this format, PA
was used as the capture antigen and alkaline phosphatase-
conjugated secondary antibody (anti-human, anti-mouse or anti-
guinea pig IgG, for the detection of chimeric, murine and guinea
pigs antibodies, respectively) was used for detection. Plates were
coated with 5 mg/ml of purified PA (50 ml/well) in NaHCO3 buffer
(50 mM, pH 9.6) at 37uC for 4 hours and then blocked with TSTA
buffer (50 mM Tris pH 7.6, 142 mM sodium chloride, 0.05%
sodium azide, 0.05% Tween 20, 2% BSA) at 37uC for 2 hours.
Tested samples (cell culture supernatant, sera or ascitic fluids,
diluted 1:50 in TSTA) were serially diluted by two-fold dilutions,
and the plates were then incubated for 2 hours at 37uC. Plates were
washed with PBS containing 0.05% Tween 20, incubated with the
detecting antibody, and then developed using p-nitrophenyl
phosphate (Sigma St. Louis, MO, USA) as a substrate prior to
measuring absorbance at 405 nm. The endpoint was defined as the
highest dilution in which absorbance was higher than two standard
deviations above the negative control (normal mouse serum).
Antibody titers were expressed as the reciprocal endpoint dilution.
Indirect-ELISA was performed using Rabbit anti-PA as the capture
antibody for PA. All tests were performed in duplicate, and both
negative controls (normal mouse serum) and positive standards (PA
hyperimmune mouse serum) were added to each plate.
Animal studies
All animal experiments were performed in accordance with the
Israeli law and were approved by the Ethics Committee for
Animal Experiments at the Israel Institute for Biological Research.
Animals were maintained at 20–22uC and a relative humidity of
50610% on a 12-h light/dark cycle, fed with commercial rodent
chow (Koffolk Inc.), and provided with tap water ad libitum.
Treatment of animals was in accordance with regulations outlined
in the USDA Animal Welfare Act and the conditions specified in
the Guidance for Care and Use of Laboratory Animals (National
Institute of Health, 1996). Animal studies were approved by the
local ethical committee on animal experiments.
Mouse immunization
Primary immunization was performed using a group of 8 mice
by s.c. injections. For the 1
st injection, 50 mg PA were emulsified
with complete Freund’s adjuvant. Two subcutaneous (s.c.) booster
injections with 50 mg PA emulsified with incomplete Freund’s
adjuvant were administered every 2 weeks. The mouse with the
highest neutralizing antibody titer received an additional i.v. boost
of 5 mg PA in PBS four days prior to spleen removal.
Cell fusion and screening
Four days after the final boost, the spleen of the mouse with the
highest neutralizing antibody titer was removed and splenocytes
were fused to NS0 mouse myeloma cells using polyethylene glycol,
as described previously [16,17]. After fusion, the cells were plated
in 96-well cell culture plates (Nunc), at 0.5 cell per well. Selection
of hybridomas was achieved by growing the cells in HAT
(hypoxantine-aminopterin-thymidine) medium (Biological Indus-
trial, Beit Haemek, Israel), and clones were observed in about 40%
of the wells. Cell clones were screened for neutralizing antibody
production, as described below. Positive hybridomas were cloned
at least twice by limiting dilution. Cloned hybridomas were
propagated both in tissue culture and in Balb/C mice.
Cloning and expression of the murine-human chimeric
29 antibody
Chimerization of the murine 29 antibody (mAb 29) included the
amplification and cloning ofthe murine VH andVL genes,encoding
the antibody variable regions, followed by murine-human chimeric
antibody expression. Total RNA was isolated from the murine anti-
PA hybridoma 29 cells using TrizolH LS reagent (Invitrogen) and
cDNA was synthesized using oligo (dT)15 primer, M-MLV and
AMV reverse transcriptases (Promega, Madison, WI, USA).
Amplification of the heavy and the light variable genes (VH and
VL) was carried out using a panel of primers directed at the 59 of
framework 1 of each gene (essentially as described [18]), and to the
constant region (CH1o rC k, respectively) at the 39 end. The mAb
anti-PA 29 antibody variable segments were amplified using the
primers pairs: 59 CAG GTY CAR CTG CAG CAG YCT GG 39;
59 TGC AGA GAC AGT GAC CAG AGT CCC 39 and 59 GAY
ATC CAG ATG ACH CAR WC 39;5 9 GGG GTA GAA GTT
GTT CAA GAA GC 39 for the VH and the VL genes, respectively.
Following sequencing, the variable genes were re-amplified using
non-degenerate primers introducing restriction sites at both ends for
cloning into a pCMV-based antibody expression vector( 59 TTA
AGA GGT GTA CAG TGT CAG GTT CAA CTG CAG CAG
TCT 39;5 9 GCC CTT GGT GCT AGC TGC AGA GAC AGT
GAC CAG AGT CCC 39 and 59 CTC TGG CTG CCC GGG
GCC AAA TGT GAT ATC CAG ATG ACA CAG AC 39;5 9
GGC AGC CAC CGT ACG TTT GAT TTC CAG CTT GGT
GCC TCC 39 for the VH and the VL genes, respectively). The
amplified heavy and light variable genes were separately purified,
digested and cloned into appropriate mammalian full-length Ig
expression vectors, providing each chain with a corresponding
signal-peptide and constant gene, resulting in IgG1/k murine-
human chimeric antibody expression.
Stable cell line establishment
CHO cells (ACC126) were transfected with the Ig expression
vector containing both heavy and light chains of the chimeric 29
antibody (cAb 29) using FuGENE 6 reagent (Roche, Mannheim,
Germany). Highly anti-PA antibody producing clones were
selected and expanded based on antibody levels in the superna-
tant, as tested by PA-specific ELISA.
cAb29, a Novel anti-PA Ab
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Mouse IgG anti-PA monoclonal antibody (mAb 29) was
produced in ascitic fluid, and chimeric anti-PA monoclonal
antibody (cAb 29) was produced from a recombinant CHO cell
line. The murine/chimeric anti-PA antibodies were purified by
affinity chromatography on HiTrap Protein G/A (GE Healthcare,
Uppsala, Sweden) according to the manufacturer’s instructions,
and dialyzed against PBS pH 7.4.
Binding kinetics determination using Surface Plasmon
Resonance (SPR)
Binding constants of murine and chimeric 29 antibodies were
evaluated by SPR using a BiacoreX instrument (Biacore Inc.
Uppsala, Sweden). The assay was implemented in two different
formats. In the first format (direct), approximately 1000 resonance
units (RU) of purified PA (10 mg/ml dissolved in 10 mM of pH 5
acetate buffer at a flow rate of 10 ml/minute) were immobilized
onto a research grade CM5 sensor chip according to the
manufacturer’s instructions. In the second format (indirect), two
additional chips were constructed, wherein, approximately
5000RU of anti-mouse or anti-human antibodies [20 mg/ml in
10 mM pH 5 acetate buffer (Jackson IR Laboratories, PA, USA)]
were immobilized. All binding experiments were performed at
25
oC in HBS-EP buffer (Biacore) at a flow rate of 20 ml/min. A
blank channel was used as an on-line reference during all
injections. For affinity constant determination via the direct
format, 40 ml aliquots of the monoclonal antibodies (diluted to 5–
100 nM) were injected over immobilized PA. In the indirect
format, affinity constants were determined following injection of
PA (diluted to 100–1000 nM) over immobilized monoclonal anti-
PA antibodies (300 RU). Pulses of 8M urea or 100 mM H3PO4
were used to regenerate the PA-immobilized chip or anti-mouse/
anti-human chips, respectively. Sensogram data were analyzed
using the BIAevaluation3.2 software package. For kinetic constant
determination using the PA-immobilized chip (direct-format), a
bivalent analysis model was applied, whereas, for the anti-human/
anti-mouse chips (indirect-format), a 1:1 Langmuir binding model
was used.
In vitro LeTx neutralization assay
Neutralizing antibody titers were determined essentially as
described previously [8,19] by assessing their ability to protect
murine macrophage J774A.1 cells (ATCC, USA) against PA/LF
toxin complex (LeTx) intoxication. Tested samples were serially
diluted by two-fold dilutions in TSTA buffer containing PA (5 mg/
ml) and LF (2 mg/ml), and after a one hour incubation, 10 mlo f
each of the reaction mixture dilutions was added to the J774A.1
cells (6–8610
5 cells/0.2 ml). Plates were then incubated for
5 hours at 37uCi n5 %C O 2, and cell viability was monitored by
the MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5- Diphenyltetrazolium
bromide; Thiazolyl blue) assay (absorbance was measured at
540 nm) [20]. The endpoint was defined as the highest serum
dilution exhibiting 0.025 O.D absorbance units above that of the
corresponding dilution of the control normal serum. Neutralizing
antibody titers were expressed as the reciprocal endpoint dilutions.
In vivo neutralization experiments
Rats LeTx challenge. To evaluate the ability of the 29
(murine or chimeric) antibody to protect rats against a LeTx
challenge, Male Fisher 344 rats (200–250 g, Harlan, Israel) were
injected intramuscularly (i.m.) with various doses of antibodies
(administration volume of 100 ml in sterile PBS). Seventeen hours
later, rats were anesthetized with ketamine:xylazine (50:2 mg/kg)
and injected via the tail vein (i.v.) with LeTx, containing 20 mgP A
and 10 mg LF in 500 ml saline, and monitored for survival.
Pharmacokinetic studies. Hartleyguineapigs (females, 200–
250 g, Charles River Laboratories, Wilmington, MA) were injected
i.m. with antibodies diluted in 200 ml PBS. At different time points,
bloodsamplesweredrawnbys.c.puncture,andantibodyconcentration
was determined by ELISA. Pharmacokinetic parameters were
calculatedusingthePKsolutionssoftware(Summitresearchservices).
Protection against anthrax spore challenge. Hartley
guinea pigs were injected i.m. with various doses of antibodies
(administration volume of 200 ml in sterile PBS), and 14 hrs later
challenged by s.c. administration of 40LD50 anthrax Vollum spores.
Animal viability was monitored for at least 14 days.
Results and Discussion
Mice were immunized with a PA-based vaccine, and titer
development of either PA-neutralizing or PA-binding antibodies
was carefully monitored. Two weeks after the third PA-administra-
tion (week 6), all immunized mice had developed high anti-PA titers
of 30,000–60,000 (Fig. 1). Yet, at this time point, no measurable
neutralizing antibody titer could be detected, and therefore another
boost was given. Indeed, in four out of the eight immunized mice,
neutralizing antibody titer developed gradually, reaching a
maximum titer value of 30,000 by week 10. Five weeks later, the
neutralizing antibody titer remained constant in these four mice
(Fig. 1), yet remained negative for the other four immunized mice
(data not shown). It was noticeable that, although PA-neutralizing
antibodies titer increased several-fold in these mice, the titer of the
total anti-PA antibodies remained unchanged. These results suggest
thatthecontinuousexposuretoPA-basedvaccineinthesemicemay
have led to a specific enrichment and maturation of the desired
subset of PA-neutralizing antibodies.
Fifteen weeks after the first immunization, both PA-neutralizing
and PA-binding antibodies titers reached their maximum. The
spleen of the mouse with the highest neutralizing antibody titer (#7)
was harvested, and splenocytes were fused to NS0 mouse myeloma
cells. The fusion process yielded approximately 600 hybridoma cell
lines, which were screened to identify clones secreting antibodies
capable of neutralizing PA activity in an in vitro assay. It was found
that 101 clones displayed PA-neutralizing activities at different
levels. The clones which demonstrated the highest neutralizing
activitywerechosenforfurthersub-cloningand characterization.At
the end of this process, 19 clones with PA-neutralizing titers ranging
from 100,000 to 2,300,000, were selected (Table 1).
These 19 antibody clones were subdivided into several groups
based upon a distinguishable PA-binding pattern in direct- and
indirect-ELISA formats. The first group consisted of four clones,
and was characterized by direct- and indirect-ELISA titers over
300,000 and 80,000 respectively (direct/indirect-ELISA ratio
of$2; Table 1). In the second group (nine clones), direct-ELISA
titer was markedly lower (up to 72,000), whereas indirect-ELISA
values remained similar to those of the first group, with a direct/
indirect-ELISA ratio,0.1 (Table 1). While indirect-ELISA values
were relatively high (.400,000) in the third group, no direct-
ELISA titers could be measured for these five clones (titer,50).
Notably, one clone (#60) had no measurable ELISA titer in both
formats. These distinct binding patterns implied that these
antibodies may recognize different sites of the target molecule,
which are unequally exposed in the different ELISA formats, and
work is now in progress to characterize these clones further.
It is worth noting that the isolation of 101 positive PA-
neutralizing monoclonal antibody-secreting clones from a single
fusion process is quite unique, and we believe it can be attributed
cAb29, a Novel anti-PA Ab
PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6351to the fact that a neutralization-based immunization monitoring
and screen were applied. These results emphasize the advantages
of applying PA-neutralization functional screen, based on the
following assumptions: It was shown above that 101 out of 600
clones (17%) exhibited PA-neutralizing activity to some degree,
from which the top 20% were further selected. If we assume that
the PA-binding characteristics of the 600 primary hybridoma
clones are similar to those of the 19 selected clones, then by
applying direct PA-ELISA titer as the primary limiting criterion,
we would expect that only 20% (120 clones) would be positive.
Consequently, we can also assume that 17% of these positive
clones (20 antibodies) would be able to neutralize PA to some
extent, and from that pool the top 20% (5 antibodies) would be
selected for further analysis. Indeed, other studies that based their
primary screens on a positive PA-binding signal in direct ELISA
format were able to select only 3–10 antibodies per screen [9–14].
Moreover, the results presented here are in good agreement with
those of other studies, in which functional screens yielded, on
average, 15 clones per fusion [21].
In vitro and in vivo LeTx neutralization
Antibody #29 (mAb 29) was chosen for chimerization and
further characterization. This antibody demonstrated the highest
neutralizing activity (titer of 2.3610
6), with ELISA titers of
72610
3 and 800610
3 in the direct and indirect formats,
respectively (Table 1). A chimeric antibody, cAb 29, containing
mAb 29 variable region genes (VH and VL) fused to human
constant region genes (Cc1 and Ck, respectively) was constructed.
Subsequently, the chimeric antibody was introduced into a
mammalian expression-system and the recombinant antibody
was stably produced by CHO cells.
The ability of cAb 29 to neutralize PA-LF complex (LeTx) activity
in the J774A macrophage cell line, as compared to that of the
Figure 1. Kinetics of anti-PA and PA-neutralizing antibody
development. Average titer values of total anti-PA ELISA antibodies
(filledcircles) of eight immunized mice and LeTx neutralizingantibodytiters
(empty circles) of mice 3, 4, 5 and 7, throughout the immunization process.
Arrows indicate PA-immunization time points; Data points are mean6STD.
doi:10.1371/journal.pone.0006351.g001
Table 1. Neutralizing titers and PA-binding characteristics of selected clones.
Group Ab # Neutralizing titer (x10
3) ELISA titer (610
3) direct/indirect ELISA titer ratio
direct indirect
1 4 320 330 145 2.3
19 205 410 81 5.1
31 100 580 102 5.7
55 820 820 410 2.0
2 10 145 13 206 0.06
22 820 9 580 0.02
28 205 13 145 0.09
29 2,300 72 820 0.09
33 290 7 820 0.01
36 205 7 520 0.01
38 100 36 410 0.09
58 1,600 26 820 0.03
68 1,600 3 1,600 0.002
3 2 360 ND
a 820 NA
b
54 1,600 ND
a 410 NA
b
59 410 ND
a 1,160 NA
b
61 820 ND
a 410 NA
b
62 820 ND
a 820 NA
b
60 100 ND
a ND
a NA
b
aELISA titer values were below detection limits.
bNot applicable.
doi:10.1371/journal.pone.0006351.t001
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dose of PA-LF complex in the presence of increasing antibody
concentrations, and cell survival was determined 5 hrs later. Cell
survival was positively correlated with both cAb 29 and mAb 29
concentrations, and full protection was achieved at 4 ng/ml for both
antibodies (Fig. 2). The effective concentration of cAb 29 needed to
neutralize 50% (EC50) of the LeTx activity was determined to be
1.3 ng/ml,comparabletothatofmAb29(EC50of 1.1 ng/ml; Fig.2).
To further explore the PA-neutralizing activity of cAb 29, its in
vivo protection capacity against a LeTx challenge was tested. In this
assay, antibodies were administered (i.m.) at different doses to rats,
followed by an i.v. challenge with a lethal dose of LeTx 17 hrs later.
All untreated control animals succumbed to this challenge, with
mean time to death (MTTD) of 110 min (Fig. 3A). Treatment of
animals with up to 100 mg/kg of cAb 29 did not improve survival
rate, nor significantly prolong the MTTD (123 min). However, by
increasing the treatment doses to 150 and 200 mg/kg, survival rates
of 30 and 55% were attained (Fig. 3A). Full protection of challenged
rats was achieved by a passive transfer of 250 mg/kg cAb 29.
According to these results, a dose of 170 mg/kg cAb 29 was needed
in order to provide 50% protection (PD50). The PA-neutralizing
activity of mAb 29 was also evaluated under the same conditions as
its chimeric counterpart, demonstrating a similar dose response
(PD50 of 160 mg/kg; Fig. 3B). These results are in line with the in
vitro assay results, suggesting that the chimerization process had no
deleterious effect on the functional activity of the antibody.
Binding studies
To evaluate the PA-binding capabilities of the chimeric and
murine #29 antibodies, Surface Plasmon Resonance (SPR)
analysis was applied. Based on the binding characteristics,
demonstrated earlier by ELISA, an indirect SPR format was
applied for the kinetic measurements (Fig. 4; Table 2). Accord-
ingly, the antibodies were attached to anti-Fc antibody pre-coated
CM5 sensor chips (anti-human or anti-mouse for the cAb 29 and
the mAb 29, respectively), followed by the injection of PA at
different concentrations. Sensograms were fitted to a 1:1 Langmuir
model, and association (kon) and dissociation (koff) rate constants
were obtained for both antibodies (Table 2). The dissociation
constants (KD) deduced from these rate constants were similar for
both antibodies, with calculated values of 6.662.8 nM and
8.564.8 nM for the chimeric and murine antibodies, respectively.
When SPR analysis was performed in the direct format, in which
PA was immobilized on the sensor chip, significantly lower
affinities were obtained (Fig. 4; Table 2). In this assay format, a
divalent analysis model was used, and KD values of 3769 nM and
4467 nM were calculated for the chimeric and the murine
antibodies, respectively (Table 2). These results are in good
agreement with the ELISA binding studies, in which antibody
binding to surface-immobilized PA was impaired compared to that
of soluble PA (indirect format), indicating that the epitope
recognized by this antibody is probably disrupted when the PA
is used as the capture moiety. Taken together, the binding studies,
along with the previously described in vitro and in vivo protection
analyses, indicate that the chimeric form of the #29 antibody
retains the binding properties of its parental murine antibody.
The affinity displayed here for cAb 29 (6.6 nM) is in good
agreement with other PA-neutralizing antibodies described
previously (10–100 nM) [22–25]. Moreover, cAb 29 exhibits a
high association rate constant (kon of 10
5 M
21s
21) toward PA, and
has an exceptionally slow dissociation rate constant (koff of
6.6610
24 s
21), a feature which could be important for long term
in vivo protection against anthrax exposure.
Protection against B. anthracis challenge
As shown earlier, cAb 29 is able to efficiently prevent in vivo
intoxication with LeTx. We next examined whether this antibody
can effectively protect guinea pigs against B. anthracis infection. To
this end, the pharmacokinetic profile of the chimeric antibody and
its ability to confer protection against anthrax spore exposure in a
guinea pig model were determined.
Pharmacokinetics studies in guinea pigs
The chimeric antibody cAb 29 and its parental murine antibody,
mAb29, wereadministered(i.m.)toguinea pigs,andtheirclearance
profiles were determined by measuring the ELISA-titers of blood
samples collected at different time points (Fig. 5). It was found that
maximal antibody concentrations (Cmax) in the bloodstream were
attained (and subsequently defined as 100% concentrations)
14 hours after injection of both antibodies. In the case of cAb 29,
this level remained unchanged for the next 5 days, after which the
antibody was gradually cleared from the animals’ bloodstreams.
The calculated mean resident time (MRT) value of cAb 29 was 6.7
days. In the case of the murine antibody, however, maximal levels
were retained for only 24 hrs, displaying an MRT value of 3.3 days.
The interactions of the antibodies’ constant regions with the host
neonatal Fc receptor (FcRn) significantly affect the antibodies’
clearance profiles. Therefore, the differences between murine and
chimeric antibody pharamcokinetics are probably a reflection of their
differential interactionswiththeguineapigFcRn.These results arein
good agreement with a previous study, in which murine antibodies
cleared from guinea pigs circulation with a half-life of 3 days, while
rabbit antibodies displayed considerably longer circulatory retention
times (t1/2 of 9 days) [26]. It has also been shown that serum half-life
prolongation of therapeutic antibodies may improve clinical
outcomes, and may reduce the amount of antibodies required [27].
Protection of guinea pigs against B. anthracis infection
To test the ability of cAb 29 to protect the animals against the
anthrax infection, antibody doses of either 5, 10 or 20 mg/kg were
Figure 2. In vitro LeTx neutralization. Toxin complex (5 mg/ml PA
and 2 mg/ml LF) was pre-incubated for one hour with increasing
concentrations of cAb 29 (triangles) or mAb 29 (squares), and added to
J774A.1 mouse macrophage cells for 5 hours. Cell survival was then
determined by MTT, and was plotted as percent of untreated control
cells. Points are mean6STD of triplicate determinants.
doi:10.1371/journal.pone.0006351.g002
cAb29, a Novel anti-PA Ab
PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6351Figure 3. In vivo LeTx neutralization. Rats (n$6 for each group) were i.m. administered with the indicated doses of (A) cAb 29 or (B) mAb 29,
followed by i.v. challenge with LeTx (20 mg PA and 10 mg LF), 17 hours later. Animal survival was monitored for the next 24 hours.
doi:10.1371/journal.pone.0006351.g003
Figure 4. Kinetic analysis of mAb 29 and cAb 29 binding to PA. SPR sensograms obtained during injection of (A) 100–2000 nM of PA on anti-
human captured cAb 29 (,300 RU), refers to the direct format; or (B) 5–100 nM of cAb 29 on immobilized PA (,900 RU), refers to the indirect format.
Similar sensograms were obtained for the mAb 29 (results not shown).
doi:10.1371/journal.pone.0006351.g004
cAb29, a Novel anti-PA Ab
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anthracis Vollum spores. Under these challenge conditions, control
mice (no treatment) died within 3 days post infection, with MTTD
of 2.5 days (Fig. 6A; Table 3). When treated with antibody at a
dose of 5 mg/kg, 50% of the animals survived the challenge with a
delayed MTTD of 7 days (Fig. 6A; Table 3), significantly longer
(P,0.005) than the respective control group value. Increasing the
antibody dose to 10 and 20 mg/kg resulted in a minor
improvement in animal survival (Fig. 6A; Table 3).
It was previously shown that in addition to toxin neutralization,
the administrationof anti-PA antibodies canmarkedly attenuate the
dissemination of the bacteria in the early stages of infection, either
by a direct anti-spore activity, or by enhancing the phagocytic
uptake of bacteria by the immune system [28–30]. In this study,
MTTD was significantly delayed even at low antibody doses,
suggesting that the anti-PA antibodies affected the initial bacteria
growth. Yet, at a certain time point, antibody levels were reduced
and bacterial growth occurred. It was also demonstrated that
soluble and membrane-bound antigens can greatly enhance
antibody clearance via antigen-mediated elimination mechanisms
[27,31], prompting the speculation that in the current study,
prolongation of anti-PA antibody residence in the bloodstream may
confer improved protection. Relatively high levels of antibodies in
the blood can be reached either by administering a higher antibody
dose, or by applying a multiple dosing protocol [21,32].
We therefore decided to apply two successive antibody doses of
10 mg/kg, one before the challenge and the second at day 4, based
upon the pharmacokineticprofileof cAb 29 (Fig. 5).Ascan be seen in
Fig. 6A, this protocol indeed conferred protection, and 100% of the
animals survived the challenge. Since antibody pharmacokinetics
may vary between animal species, a half-life of up to 3 weeks is
anticipated in humans for an IgG1-type chimeric antibody. It is
therefore possible that while double administration of antibody is
needed for fullprotection in the guinea pig model,in humans, a single
administration will provide equivalent and long lasting protection.
Endogenous protective immunity against B. anthracis re-
challenge
It was shown previously that following passive immunization,
animals that survived anthrax challenge developed an endogenous
immune response toward PA [26]. It was therefore of interest to
examine whether, in our animal/antibody model, endogenous
immune response was developed and whether it would confer
protection against anthrax re-challenge. To this end, blood
samples were drawn at day 30 after infection from animals in
the groups that received cAb 29 at a total dose of 20 mg/kg (either
by a single or double administration), and assessed for their ability
to neutralize LeTx during the in vitro assay. Several days later,
animals were re-challenged by s.c. infection with 40LD50 of B.
anthracis Vollum spores and monitored for survival during the
following 14 days. In both groups, a considerable fraction of the
animals survived the second challenge, with 67% and 50%
survival for the single and double administration groups,
respectively (Fig. 6B; Table 3). All animals that survived the re-
challenge exhibited neutralizing titer value above 100 at the time
of infection, while the neutralizing titer of the non-survivors (all but
one) was below 50. Anti-human antibody ELISA of these serum
samples confirmed the absence of cAb 29, while all were found
positive for guinea pig anti-PA titer, indicating that the
neutralizing activity was endogenously derived. These results are
in good agreement with previous reports, in which it was shown
that the presence of PA-neutralizing polyclonal antibodies (either
generated by active primary immunization or passively trans-
ferred) in sera can reliably predict protection against anthrax spore
challenge [8,26,33]. In these studies, a neutralizing titer of 80
conferred 50% protection of guinea pigs and rabbits, and full
protection was achieved at a titer of 220 and above. The ability of
passive immunization (either by poly- or monoclonal antibodies) to
confer protection against anthrax infection while enabling the
development of endogenous immunity has been demonstrated
previously in several animal models [9,26,33]. These results were
explained by a certain degree of bacteria growth during the passive
Table 2. Binding kinetics of the PA-specific antibodies.
Immobilized PA (direct format)
a Immobilized anti-PA (Indirect format)
b
kon koff KD kon koff KD
(M
21s
21)( s
21) (nM) (M
21s
21)( s
21) (nM)
mab29 2.0610
5 8.9610
23 44670 . 8 610
5 6.8610
24 8.564.8
cAb29 2.0610
5 7.5610
23 37691 . 0 610
5 6.6610
24 6.662.8
aBinding kinetics values derived from global curve-fitting analysis using divalent analysis model.
bBinding kinetics values derived from global curve-fitting analysis using 1:1 Langmuir binding model.
doi:10.1371/journal.pone.0006351.t002
Figure 5. Circulatory clearance profiles of cAb 29 and mAb 29.
Guinea pigs (n=3 for each group) were i.m. administered with 5 mg/kg
of either cAb 29 (diamonds) or mAb 29 (squares). Blood samples drawn
at various time points were assayed for Ab concentration by ELISA.
Mean6STD values are presented as percentages of maximum blood
levels (Cmax).
doi:10.1371/journal.pone.0006351.g005
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active immune response. Moreover, it was hypothesized recently
that the formation of monoclonal antibody-PA complexes may act
as an immunostimulator, thereby enhancing the endogenous
immune response [9].
The results of the present study strongly support the notion that
immunization monitoring and primary selection of anti-PA
monoclonal antibodies on the basis of their in vitro toxin
neutralization activity can provide a large panel of antibodies
with the potential to protect animals from anthrax infection.
Antibody 29, which demonstrated the most potent activity among
the large panel of neutralizing antibodies identified, was able to
confer full protection of guinea pigs against B. anthracis spore
infection. The data presented in this study suggest that cAb 29 is
an excellent candidate for therapeutic preparations aimed at
providing efficient and immediate anthrax toxin neutralization,
and further evaluation of its value in other animal models is now in
progress. Moreover, other neutralizing antibodies elicited in this
screen and targeting different PA-epitopes are being evaluated,
and will be combined in therapeutic preparations for potential
synergistic effects.
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Figure 6. Protection of guinea pigs against anthrax infection. (A) Female Hartley guinea pigs (n=6 for each group) were i.m. administered
with the indicated doses of cAb 29, followed by s.c. challenge with 40LD50 of B. anthracis Vollum spores 14 hrs later. (B) 30 days after the first
challenge, surviving animals from groups 20 and 10+10 mg/kg were re-challenged with the same dose (40LD50), and survival was then monitored for
another 14 days.
doi:10.1371/journal.pone.0006351.g006
Table 3. Protection of Guinea pigs from anthrax infection by
antibody administration.
1
st challenge
a 2
nd challenge
b
Ab dose Pre-treatment
(mg/kg)
survivors/
total
MTTD
(days)
survivors/
total
MTTD
(days)
– 0/6 2.5 0/6 2
5 3/6 7
10 4/6 6.5
20 4/6 6.5 2/3
c 4.3
10+10 6/6 3/6 4
aAnimals were challenged with s.c administration of 40LD50 of B. anthracis
Vollum spores.
bAnimals that survived the 1
st challenge were re-infected with 40LD50 of B.
anthracis Vollum spores.
COne animal was omitted from re-challenged, due to bites injury.
doi:10.1371/journal.pone.0006351.t003
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